广告
加载中

巨子生物618战报:可复美止跌回升 可丽金持续增长

亿邦动力 2026-06-24 12:20
亿邦动力 2026/06/24 12:20

邦小白快读

EN
全文速览

本文核心是巨子生物2026年618大促战报的核心干货信息,核心内容整理如下:

1. 业绩层面:可复美扭转了2025年的同比下滑趋势,2026年线上全渠道GMV同比增长超25%;可丽金保持增长态势,全周期GMV同比增长超30%;对比2024年的爆发增长,双品牌增速明显放缓,巨子生物整体进入稳健增长周期。

2. 渠道层面:可复美在天猫、抖音、京东、唯品会全平台实现均衡增长,天猫美妆排名从去年的第16名升至第13名;可丽金在抖音(增速50%+)、唯品会(增速60%+)的增长表现远好于可复美。

3. 产品层面:品牌核心单品数量从去年11款增至17款,多为老品延续和升级,同时有多个新品成功打入核心矩阵,可复美4月推出的超透棒上市首周全渠道GMV破3000万元,新品接力效果明显。

本文为功能性护肤品牌的战略布局提供了参考干货,核心内容整理如下:

1. 品牌增长层面:多品牌梯度布局可以对冲单品牌增长波动风险,巨子生物可复美去年下滑、今年止跌,可丽金持续保持高增长,双品牌搭配让整体维持稳健增长,这种布局模式值得同赛道品牌参考。

2. 渠道布局层面:成熟品牌可走全渠道均衡增长路线,分散单一渠道依赖风险;上升期品牌可以重点发力抖音、唯品会等渠道,获得更高的增速增量,可丽金在两个渠道的增速分别达到50%+、60%+,验证了该策略的有效性。

3. 产品布局层面:当前市场趋势是搭建多核心单品矩阵,品牌需要通过老品升级、新品接力的方式,降低对少数固定爆品的依赖,这种打法可以有效延长品牌增长周期,新品的成功也能为品牌带来新增量。

对于美妆护肤类电商卖家,本文透露出赛道的增长变化和机会风险,核心干货整理如下:

1. 行业增长层面:当前功能性护肤赛道已经从2024年之前的爆发式增长,进入到稳健增长周期,头部品牌双品牌增速从原来的60%、100%回落至25%、30%,卖家需要调整增长预期,不要盲目追求高爆发。

2. 渠道机会层面:全渠道均衡布局可以获得稳定增长,抖音和唯品会仍然有较高的增长红利,可丽金在两个平台的增速远超传统平台,卖家可以针对性加大这两个渠道的布局投入。

3. 产品与风险层面:单一爆品的增长风险较高,头部品牌也会出现单品牌下滑的情况,卖家可以学习头部品牌的做法,通过老品升级+新品推新搭建多核心产品矩阵,对冲单一产品下滑的风险,目前新品只要打中需求就能快速起量,存在不少机会。

对于重组胶原蛋白护肤领域的生产工厂,本文透露出产品需求和商业机会,核心干货整理如下:

1. 生产设计需求层面:当前品牌方已经从依赖少数大爆品,转向搭建多核心单品矩阵,头部品牌巨子生物的核心单品数量已经从11款增至17款,涵盖延续款、升级款、全新款三类产品,这要求工厂具备柔性生产能力,能够适配多SKU、小批量、快速交付的需求,同时也要有配合品牌做产品升级研发对接的能力。

2. 商业机会层面:头部品牌正在持续扩充产品矩阵,新品放量速度快,可复美超透棒上市首周GMV就突破3000万元,对应可观的生产订单量,工厂可以针对性对接头部品牌的新品需求,获取更多订单。

3. 发展启示层面:当前重组胶原蛋白护肤赛道仍然保持稳健增长,头部品牌创新需求旺盛,工厂需要持续跟进相关产品的技术升级,提升自身的研发生产配套能力,才能抓住行业增长的机会。

对于服务美妆品牌的各类服务商,本文透露出行业趋势和客户需求,核心干货整理如下:

1. 行业发展趋势:当前功能性护肤赛道已经从早期的爆发式增长进入稳健增长周期,头部品牌不再一味追求爆发式增速,转而追求可持续的稳定增长,服务商需要调整自身的服务目标,匹配品牌新的增长需求。

2. 客户核心痛点:多数品牌都存在单品牌、单爆品依赖的增长瓶颈,头部品牌可复美就曾经出现同比下滑的情况,品牌都在寻求破解增长瓶颈、降低经营风险的方法,这给服务商带来了新的服务机会。

3. 业务机会:品牌当前有两大核心服务需求,一是多平台差异化运营需求,成熟品牌要全渠道增长、上升品牌要重点渠道突破,服务商可以推出针对性方案;二是新品打爆服务需求,品牌持续扩充核心单品,需要服务商提供新品冷启动增量服务,市场需求较大。

对于美妆电商平台,本文透露出品牌的渠道需求和平台运营方向,核心干货整理如下:

1. 品牌渠道需求:不同发展阶段的品牌渠道需求不同,成熟品牌比如可复美追求全渠道均衡增长,希望各个平台都能贡献稳定增量;上升期品牌比如可丽金更倾向于重点突破少数高增长渠道,抖音、唯品会是当前品牌的优先选择。

2. 平台招商机会:唯品会目前的增长表现十分突出,可复美在该平台增速超40%,可丽金增速超60%,远高于传统平台,平台可以突出自身的高增长优势,吸引更多品牌入驻布局。

3. 平台运营方向:当前品牌普遍在持续推新,对平台的新品流量扶持、冷启动运营支持需求较高,平台可以针对性推出新品扶持政策,吸引品牌带新品入驻,同时头部品牌整体增速放缓,平台需要提前挖掘新品牌新供给,对冲头部增长放缓的风险。

对于护肤产业研究者,本文反映出国内重组胶原蛋白赛道的最新产业动向,核心干货整理如下:

1. 产业发展阶段变化:头部企业巨子生物的双品牌增速从2024年的60%、100%,回落至2026年的25%、30%,说明国内重组胶原蛋白护肤赛道已经从早期的爆发式增长,进入到稳健增长的成熟阶段,行业逐步进入存量竞争阶段。

2. 头部企业战略新动向:面对增长放缓,头部企业已经调整产品战略,从过去打造单一爆品的模式,转向构建多核心单品矩阵,通过老品升级+新品接力的方式降低增长风险,可复美核心单品从11款增至17款就是典型案例。

3. 产业结构新变化:多品牌梯度增长的模式已经验证效果,可复美止跌回升、可丽金保持高增长,说明多品牌战略可以有效对冲单品牌增长瓶颈;渠道端抖音、唯品会等新兴渠道成为核心增长极,渠道结构正在发生重构,值得深入研究。

返回默认

声明:快读内容全程由AI生成,请注意甄别信息。如您发现问题,请发送邮件至 run@ebrun.com 。

我是 品牌商 卖家 工厂 服务商 平台商 研究者 帮我再读一遍。

Quick Summary

This article compiles key takeaways from Giant Biotech's 2026 618 mid-year shopping festival performance report:

1. Performance: Comfy has reversed its year-on-year decline in 2025, with its full online GMV growing more than 25% year-on-year in 2026. Clinican continues its growth trend, with full-cycle GMV growing over 30% year-on-year. Compared with its explosive growth in 2024, the growth rate of the dual brands has slowed significantly, and Giant Biotech as a whole has entered a steady growth cycle.

2. Channels: Comfy achieved balanced growth across all major platforms including Tmall, Douyin, JD.com and Vipshop, rising from 16th to 13th place in Tmall's beauty category ranking. Clinican delivered far stronger growth than Comfy on Douyin (over 50% growth) and Vipshop (over 60% growth).

3. Products: The number of the group's core SKUs increased from 11 last year to 17, most of which are upgraded iterations of existing products, while multiple new products have successfully entered the core product matrix. Comfy's newly launched Super Transparent Stick, introduced in April, generated over 30 million RMB in full-channel GMV in its first week on the market, demonstrating strong new product momentum.

This article offers key insights for strategic planning for functional skincare brands:

1. Brand growth: A multi-brand tiered portfolio can hedge against growth volatility from single-brand dependence. After Giant Biotech's Comfy declined last year and returned to growth this year, while Clinican maintained strong double-digit growth, the dual-brand structure delivered steady overall group growth. This layout model is a valuable reference for brands in the same segment.

2. Channel strategy: Mature brands can pursue an omni-channel balanced growth approach to reduce the risk of over-reliance on a single channel. Growth-stage brands can prioritize high-potential channels like Douyin and Vipshop to capture higher incremental growth. Clinican's 50%+ growth on Douyin and 60%+ growth on Vipshop validates the effectiveness of this strategy.

3. Product strategy: The current market trend is to build a multi-core SKU matrix. Brands can reduce dependence on a small number of established blockbuster products through upgrading existing offerings and rolling out new products in sequence, an approach that effectively extends the brand's growth cycle and unlocks new incremental growth from successful new launches.

This article outlines key growth shifts, opportunities and risks for beauty and skincare e-commerce sellers:

1. Industry growth: The functional skincare segment has shifted from the explosive growth seen before 2024 into a steady growth cycle. Growth rates for the two leading brands of Giant Biotech have slowed from 60% and 100% to 25% and 30% respectively. Sellers should adjust their growth expectations and avoid chasing unrealistic explosive growth blindly.

2. Channel opportunities: An omni-channel balanced layout delivers more stable growth, and Douyin and Vipshop still offer significant growth dividends. Clinican's growth on both platforms far outpaced traditional platforms, so sellers can consider increasing investment and布局 in these two channels.

3. Product and risk mitigation: Relying on a single blockbuster product carries high growth risk, even leading brands can face single-brand revenue decline. Sellers can learn from leading brands by building a multi-core product matrix through upgrading existing products and launching new offerings to hedge against the risk of a single product declining. Today, new products that match market demand can scale quickly, creating no shortage of opportunities.

This article reveals product demand and business opportunities for manufacturers in the recombinant collagen skincare space:

1. Production and design requirements: Brands have shifted from relying on a small number of blockbusters to building a multi-core SKU matrix. Leading player Giant Biotech has expanded its core SKU count from 11 to 17, covering incremental updates, upgraded versions and entirely new products. This requires manufacturers to have flexible production capabilities to adapt to demand for multiple SKUs, small-batch runs and fast delivery, as well as the R&D capacity to partner with brands on product upgrade projects.

2. Business opportunities: Leading brands are continuously expanding their product matrices, and new products can scale very quickly. For example, Comfy's Super Transparent Stick hit 30 million RMB in GMV in its first week, translating to substantial production orders. Factories can proactively partner with leading brands to meet their new product demand and secure more orders.

3. Strategic takeaways: The recombinant collagen skincare segment is still growing steadily, and leading brands have strong demand for product innovation. Factories need to keep up with related product technology upgrades and improve their integrated R&D and production capabilities to capitalize on industry growth opportunities.

This article outlines industry trends and client demand for service providers working with beauty brands:

1. Industry trends: The functional skincare segment has shifted from early-stage explosive growth to a steady growth cycle. Leading brands are no longer chasing breakneck growth, instead prioritizing sustainable, stable growth. Service providers need to adjust their service objectives to match brands' new growth requirements.

2. Core client pain points: Most brands face growth bottlenecks from over-reliance on a single brand or single blockbuster product—even leading brand Comfy experienced a year-on-year decline. Brands are actively seeking solutions to break growth bottlenecks and reduce operational risk, which creates new service opportunities for providers.

3. Business opportunities: Brands currently have two core service demands. First, they need differentiated operation support for multiple platforms: mature brands need omni-channel growth, while growth-stage brands need support to break through in high-priority channels, so service providers can develop tailored solutions for each. Second, there is strong market demand for new product launch services, as brands continuously expand their core SKU portfolios and need support for cold start and initial incremental growth.

This article outlines brands' channel demand and implications for e-commerce beauty platform operation:

1. Brands' channel demand: Brands at different development stages have different channel needs. Mature brands like Comfy pursue balanced omni-channel growth and expect steady incremental growth from every platform. Growth-stage brands like Clinican prioritize breaking out in a small number of high-growth channels, with Douyin and Vipshop currently the top choices for brands.

2. Merchant acquisition opportunities: Vipshop has delivered particularly strong growth recently: Comfy notched over 40% growth on the platform, while Clinican grew over 60%, far outperforming traditional platforms. Platforms can highlight their high-growth advantages to attract more brands to set up shop on their platforms.

3. Platform operation priorities: Brands are consistently launching new products today, so they have strong demand for new product traffic support and cold-start operation assistance from platforms. Platforms can launch targeted new product support policies to attract brands to bring new launches to their platforms. At the same time, as leading brands see slower overall growth, platforms need to proactively cultivate new brands and new supply to hedge against the risk of slowing growth from incumbents.

This article presents the latest industry developments in China's recombinant collagen skincare segment for industry researchers:

1. Industry development stage shift: Growth rates for the two leading brands of top player Giant Biotech slowed from 60% and 100% in 2024 to 25% and 30% in 2026, indicating that China's recombinant collagen skincare segment has transitioned from early-stage explosive growth to a mature stage of steady expansion, and the industry is gradually entering a period of stock competition.

2. New strategic moves by leading incumbents: In response to slowing growth, leading players have adjusted their product strategy: shifting from the traditional model of building a single blockbuster to constructing a multi-core SKU matrix, reducing growth risk through upgrading existing products and rolling out new products in sequence. Giant Biotech's expansion of core SKUs from 11 to 17 is a typical example of this shift.

3. New changes in industrial structure: A tiered multi-brand growth model has now been proven effective. Comfy's return to growth after a decline and Clinican's continued strong growth shows that a multi-brand strategy can effectively hedge against single-brand growth bottlenecks. On the channel side, emerging platforms such as Douyin and Vipshop have become core growth drivers, leading to an ongoing restructuring of channel structure that merits further in-depth research.

Disclaimer: The "Quick Summary" content is entirely generated by AI. Please exercise discretion when interpreting the information. For issues or corrections, please email run@ebrun.com .

I am a Brand Seller Factory Service Provider Marketplace Seller Researcher Read it again.

【亿邦原创】6月23日,巨子生物公布2026年618大促战报:可复美线上全渠道GMV同比增长超25%,可丽金全周期GMV同比增长超30%。

2025年,巨子生物未发布618大促战报。据招银国际研报,2025年5月至6月,可复美和可丽金在天猫淘宝及抖音的合计GMV为10.8亿元,同比增长2%。其中,可复美同比减少2%,可丽金同比增长33%。对比去年,可复美成功扭转了下滑趋势,可丽金则保持了增长态势。

对比2024年,巨子生物旗下品牌的增速有所下降。2024年618期间,可复美线上全渠道全周期GMV同比增长超60%,可丽金同比增长超100%。2026年双品牌25%与30%的增速,较2024年的爆发期大幅放缓,表明巨子生物整体已进入相对稳健的增长周期。

从平台来看,可复美在天猫(20%+)、抖音(25%+)、京东(30%+)、唯品会(40%+)呈现相对均衡的增长态势,且天猫美妆排名由去年的第16名升至第13名。相比之下,可丽金在抖音(50%+)和唯品会(60%+)的增速显著高于可复美。

在产品端,战报披露的核心单品数量由去年的11款增至17款,其中9款为延续性大单品,2款升级为2.0版本(可复美胶原棒2.0、可复美胶原乳2.0)。新核心品和升级品仍集中于可复美品牌,证明其正试图降低对重组胶原蛋白敷料、焦点面霜等固定爆品的依赖。

在巨子生物2026年推出的新品中,可复美4月上市的“超透棒”上市首周全渠道自营GMV破3000万元,起到了较好的新品接力作用;可丽金在618前上市的“胶卷小金瓶”与“胶卷水乳”,也成功跻身此次大促的核心品矩阵。

亿邦持续追踪报道该情报,如想了解更多与本文相关信息,请扫码关注作者微信。

文章来源:亿邦动力

广告
微信
朋友圈

这么好看,分享一下?

朋友圈 分享

APP内打开

+1
+1
微信好友 朋友圈 新浪微博 QQ空间
关闭
收藏成功
发送
/140 0